Author: admin

DelveInsight’s, “Obstructive Sleep Apnea Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Obstructive Sleep Apnea pipeline landscape. It covers the Obstructive Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obstructive Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Obstructive Sleep Apnea Pipeline Report

• DelveInsight’s Obstructive Sleep Apnea pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Obstructive Sleep Apnea treatment.
• The leading companies working in the Obstructive Sleep Apnea Market include Apnimed, Therapix Biosciences, Eisai, Idorsia Pharmaceuticals, Takeda, Merck & Co, Taisho Pharmaceutical Co., Ltd., Bayer, Janssen Pharmaceuticals, RespireRx Pharmaceuticals, Cortex Pharmaceuticals, Michael James Enterprises, and others.
• Promising Obstructive Sleep Apnea Pipeline Therapies in the various stages of development include AL539 (SRETT), Lemborexant 10 mg, Sulthiame, Eszopiclone, AD182, AD504, Atomoxetine, and others.
• December 2023: Nyxoah S.A., A multicenter study to assess the safety and effectiveness of the Genio dual-sided hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in adults subjects.
• December 2023: University of Calgary, The primary objective of this study is to evaluate the effect of more timely care for obstructive sleep apnea (OSA) on adherence to positive airway pressure (PAP) therapy at three months after treatment initiation. The secondary objectives are to determine if earlier care improves the treatment effect of PAP on patient reported sleepiness, quality of life and patient satisfaction. We will also evaluate the impact of shorter wait times on patient engagement in therapy by assessing initial acceptance of PAP therapy, patient activation and self-efficacy with respect to OSA treatment.

Request a sample and discover the recent advances in Obstructive Sleep Apnea Treatment Drugs @ Obstructive Sleep Apnea Pipeline Outlook Report

In the Obstructive Sleep Apnea Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Obstructive Sleep Apnea NDA approvals (if any), and product development activities comprising the technology, Obstructive Sleep Apnea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Obstructive Sleep Apnea Overview

Obstructive sleep apnea (OSA) is characterized by episodes of breathing cessation or shallow breathing in sleep. These episodes are due to complete or partial collapse of upper airway. Most of the time, the respiratory events are associated with snoring, oxygen desaturations and brief arousal from sleep.

Find out more about Obstructive Sleep Apnea Therapeutics Assessment @ Obstructive Sleep Apnea Preclinical and Discovery Stage Products

Obstructive Sleep Apnea Emerging Drugs Profile

• Lemborexant : Eisai
• Sulthiame : Desitin Arzneimittel GmbH
• AD 182 : Apnimed
• TAK-925 : Takeda

Obstructive Sleep Apnea Pipeline Therapeutics Assessment

There are approx. 20+ Obstructive Sleep Apnea companies which are developing the Obstructive Sleep Apnea therapies. The Obstructive Sleep Apnea companies which have their Obstructive Sleep Apnea drug candidates in the most advanced stage, i.e. phase II include, Desitin Arzneimittel GmbH.

Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal 

Learn more about the emerging Obstructive Sleep Apnea Pipeline Therapies @ Obstructive Sleep Apnea Clinical Trials Assessment

Obstructive Sleep Apnea Pipeline Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Scope of the Obstructive Sleep Apnea Pipeline Report

• Coverage- Global
• Obstructive Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Obstructive Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Obstructive Sleep Apnea Companies- Apnimed, Therapix Biosciences, Eisai, Idorsia Pharmaceuticals, Takeda, Merck & Co, Taisho Pharmaceutical Co., Ltd., Bayer, Janssen Pharmaceuticals, RespireRx Pharmaceuticals, Cortex Pharmaceuticals, Michael James Enterprises, and others.
• Obstructive Sleep Apnea Pipeline Therapies- AL539 (SRETT), Lemborexant 10 mg, Sulthiame, Eszopiclone, AD182, AD504, Atomoxetine, and others.

Dive deep into rich insights for new drugs for Obstructive Sleep Apnea Treatment, Visit @ Obstructive Sleep Apnea Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Obstructive Sleep Apnea: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Obstructive Sleep Apnea– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Sulthiame : Desitin Arzneimittel GmbH
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Obstructive Sleep Apnea Key Companies
21. Obstructive Sleep Apnea Key Products
22. Obstructive Sleep Apnea- Unmet Needs
23. Obstructive Sleep Apnea- Market Drivers and Barriers
24. Obstructive Sleep Apnea- Future Perspectives and Conclusion
25. Obstructive Sleep Apnea Analyst Views
26. Obstructive Sleep Apnea Key Companies
27. Appendix

For further information on the Obstructive Sleep Apnea Pipeline therapeutics, reach out to Obstructive Sleep Apnea Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obstructive Sleep Apnea Pipeline, FDA Approvals, Clinical Trials Studies, Emerging Drugs, and Latest News 2024 (Updated)

DelveInsight’s, “Peanut Allergy Pipeline Insight 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Peanut Allergy pipeline landscape. It covers the Peanut Allergy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peanut Allergy Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Peanut Allergy Pipeline Report

• DelveInsight’s Peanut Allergy Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Peanut Allergy treatment.
• The leading companies working in the Peanut Allergy Market include DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others.
• Promising Peanut Allergy Pipeline Therapies in the various stages of development include Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others.
• January 2024: Allergy Therapeutics announced a study of Phase 1 clinical trials for VLP Peanut. This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
• January 2024: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for Remibrutinib. A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed allergy to peanuts. The efficacy will be measured by the ability of participants to tolerate increasing doses of peanut protein during an oral food challenge after 1 month of study treatment.
• January 2024: DBV Technologies announced a study of Phase 3 clinical trials for DBV712. The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month treatment period.

Request a sample and discover the recent advances in Peanut Allergy Treatment Drugs @ Peanut Allergy Pipeline Outlook Report

In the Peanut Allergy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Peanut Allergy NDA approvals (if any), and product development activities comprising the technology, Peanut Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Peanut Allergy Overview

A peanut allergy is a reaction that occurs when your body mistakenly identifies peanuts as harmful substances. When you eat peanuts or food containing peanuts, your immune system —the body’s natural defense system that fights infections and diseases—overreacts and can cause a serious, even life-threatening response.

Find out more about Peanut Allergy Therapeutics Assessment @ Peanut Allergy Preclinical and Discovery Stage Products

Peanut Allergy Emerging Drugs Profile

• Viaskin Peanut: DBV Technologies
• Dupilumab: Regeneron Pharmaceuticals/Sanofi
• CNP-201: Cour Pharmaceutical

Peanut Allergy Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the Peanut Allergy therapies. The Peanut Allergy companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. preregistration include, DBV Technologies.

Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intradermal
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Learn more about the emerging Peanut Allergy Pipeline Therapies @ Peanut Allergy Clinical Trials Assessment

Peanut Allergy Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Scope of the Peanut Allergy Pipeline Report

• Coverage- Global
• Peanut Allergy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peanut Allergy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Peanut Allergy Companies- DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others.
• Peanut Allergy Pipeline Therapies- Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others.

Dive deep into rich insights for new drugs for Peanut Allergy Treatment, Visit @ Peanut Allergy Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Peanut Allergy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Preregistration)
7. Viaskin Peanut: DBV Technologies
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Dupilumab: Regeneron Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. CNP-201: Cour Pharmaceutical
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Peanut-NE01 vaccine: BlueWillow Biologics
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Peanut Allergy Key Companies
20. Peanut Allergy Key Products
21. Peanut Allergy Unmet Needs
22. Peanut Allergy Market Drivers and Barriers
23. Peanut Allergy Future Perspectives and Conclusion
24. Peanut Allergy Analyst Views
25. Peanut Allergy Companies
26. Appendix

For further information on the Peanut Allergy Pipeline therapeutics, reach out to Peanut Allergy Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peanut Allergy Pipeline, FDA Approvals, Clinical Trials Assessment, Emerging Drugs, Latest News 2024 (Updated)

DelveInsight’s, “Heart Failure Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Heart Failure pipeline landscape. It covers the pipeline drug profiles, including Heart Failure clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Heart Failure Pipeline Report

• DelveInsight’s Heart Failure Pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Heart Failure treatment. 
• The leading Heart Failure Companies includes Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol-Myers Squibb, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, BIAL, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others. 
• Promising Heart Failure Pipeline Therapies include CXL-1020, Strata 1 CXL-1020, Ularitide, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer’s Solution, Bisoprolol, Empagliflozin, Lixivaptan, and others.
• January 2024: AstraZeneca announced a study of Phase 2 clinical trials for AZD3427. This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2.
• January 2024: Bayer announced a study of Phase 3 clinical trials for Finerenone (BAY94-8862). The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits for HF(generally meaning a hospital stay or urgent presentation to a healthcare unit due to worsening symptoms of heart failure) in patients suffering from HF with an ejection fraction greater than or equal to 40%.
• January 2024: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for Sacubitril/valsartan. This is a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.

Request a sample and discover the recent advances in Heart Failure Treatment Drugs @ Heart Failure Pipeline Outlook Report

In the Heart Failure pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Heart Failure clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Heart Failure Overview

Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations. 

Find out more about the Heart Failure Diagnosis and Treatment of patients @ Heart Failure Ongoing Clinical Trials Analysis

Heart Failure Emerging Drugs 

• Tirzepatide: Eli Lilly and Company 
• Finerenone (BAY94-8862): Bayer  
• CardiAMP Cell Therapy: BioCardia 
• Firibastat: Quantum Genomics 
• HU 6: Rivus Pharmaceuticals

Heart Failure Therapeutics Assessment

There are approx. 75+ Heart Failure companies which are developing the therapies for Heart Failure. The Heart Failure companies which have their Heart Failure drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.

Heart Failure Route of Administration

Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Discover more about the list of Heart Failure FDA-approved drugs @ Heart Failure Treatment Landscape

Heart Failure Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Scope of the Heart Failure Pipeline Report

• Coverage- Global
• Heart Failure Companies- Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol-Myers Squibb, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, BIAL, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others. 
• Heart Failure Pipeline Therapies- CXL-1020, Strata 1 CXL-1020, Ularitide, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer’s Solution, Bisoprolol, Empagliflozin, Lixivaptan, and others. 
• Heart Failure Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Heart Failure Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for Heart Failure Emerging Therapies and Ongoing Clinical Trials; visit @ Heart Failure Emerging Therapies and Companies

Table of Content

1. Introduction
2. Heart Failure Executive Summary
3. Heart Failure Overview
4. Heart Failure Pipeline Therapeutics
5. Heart Failure Therapeutic Assessment
6. Heart Failure – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tirzepatide: Eli Lilly and Company
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. HU 6: Rivus Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. HiCM 188: Help Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Heart Failure Collaborations Assessment- Licensing / Partnering / Funding
18. Heart Failure Unmet Needs
19. Heart Failure Market Drivers and Barriers
20. Appendix

Got Queries? Find out the related information on Heart Failure Mergers and acquisitions, Heart Failure Licensing Activities @ Heart Failure Emerging Drugs, and Recent Trends

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Heart Failure Pipeline, FDA Approvals, Clinical Trials Assessment, Emerging Drugs, and Companies 2024 (Updated)

DelveInsight’s, “Cystic Fibrosis Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Cystic Fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cystic Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Cystic Fibrosis Pipeline Report

• DelveInsight’s Cystic Fibrosis pipeline report depicts a robust space with 75+ companies working to develop 80+ pipeline therapies for Cystic Fibrosis treatment.
• The leading companies working in the Cystic Fibrosis Market include Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
• Promising Cystic Fibrosis Pipeline Therapies in the various stages of development include Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.
• January 2024: 4D Molecular Therapeutics announced a study of Phase 1 & 2 clinical trials for 4D-710. This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with CF who are ineligible for or unable to tolerate CFTR modulator therapy.
• January 2024: Vertex Pharmaceuticals Incorporated announced a study of Phase 1 clinical trials for VX.522 mRna therapy. The purpose of this study is to evaluate the safety and tolerability of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.

Request a sample and discover the recent advances in Cystic Fibrosis Treatment Drugs @ Cystic Fibrosis Pipeline Outlook Report

In the Cystic Fibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystic Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Cystic Fibrosis Overview

Cystic fibrosis is a progressive, genetic disease that causes long-lasting lung infections and limits the ability to breathe over time. More than 30,000 children and adults in the United States have CF (70,000 worldwide) and CF affects people of every racial and ethnic group.

Find out more about Cystic Fibrosis Therapeutics Assessment @ Cystic Fibrosis Preclinical and Discovery Stage Products

Cystic Fibrosis Emerging Drugs Profile

• OligoG: Algi Pharma
• Ensifentrine: Verona Pharma
• MRT5005: Translate Bio
• CB280: Calithera Biosciences
• KB407 : Krystal Biotech
• SPL84231: SpliSense

Cystic Fibrosis Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the Cystic Fibrosis therapies. The Cystic Fibrosis companies which have their Cystic Fibrosis drug candidates in the most advanced stage, i.e. phase II include, Algi Pharma.

Learn more about the emerging Cystic Fibrosis Pipeline Therapies @ Cystic Fibrosis Clinical Trials Assessment

Scope of the Cystic Fibrosis Pipeline Report

• Coverage- Global
• Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cystic Fibrosis Companies- Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxosmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
• Cystic Fibrosis Pipeline Therapies- Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.

Dive deep into rich insights for new drugs for Cystic Fibrosis Treatment, Visit @ Cystic Fibrosis Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Cystic Fibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cystic Fibrosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. OligoG : Algi pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CB280:Calithera Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. SPL84231: Spli Sense
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cystic Fibrosis Key Companies
21. Cystic Fibrosis Key Products
22. Cystic Fibrosis Unmet Needs
23. Cystic Fibrosis Market Drivers and Barriers
24. Cystic Fibrosis Future Perspectives and Conclusion
25. Cystic Fibrosis Analyst Views
26. Cystic Fibrosis Companies
27. Appendix

For further information on the Cystic Fibrosis Pipeline therapeutics, reach out to Cystic Fibrosis Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cystic Fibrosis Pipeline, FDA Approvals, Clinical Trials, Emerging Therapies and Companies 2024 (Updated)

[Las Vegas, United States]  (29 January 2024) The Latest report, AVASTIN Market Size, Forecast, and Drug Insight 2032 is published by DelveInsight, a leader in healthcare research firm, providing insights into the AVASTIN market landscape and market forecast of AVASTIN up to 2032. This report is now available for review and analysis.

Are you interested in finding out the projected market size of AVASTIN in 2032? Click @ AVASTIN Market Size

The AVASTIN Market Report offers projected sales forecasts for AVASTIN for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products for Glioblastoma Multiforme. It also covers analyst views along with market drivers and barriers.

Do you know your drug’s competitive positioning against AVASTIN? Download Report: AVASTIN Market Outlook

AVASTIN is serving as a beacon of hope for patients suffering from the Glioblastoma Multiforme.

Avastin, known by the generic name bevacizumab, is a medication employed in the management of wet age-related macular degeneration (AMD). Additionally, it is utilized for the treatment of diabetic eye disease and various retina-related issues. Administered through eye injections, Avastin aids in mitigating the progression of vision impairment associated with these conditions.

The report extensively covers the details and developments related to AVASTIN, capturing important highlights on the developmental pipeline, regulatory status and special designations of AVASTIN, route of administration, safety and efficacy details.

AVASTIN Market Assessment

This report provides a detailed market assessment of AVASTIN for Glioblastoma Multiforme in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

AVASTIN Clinical Assessment

The report provides the clinical trials information of AVASTIN for Glioblastoma Multiforme covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.  

AVASTIN Competitive Landscape 

The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the AVASTIN.

AVASTIN Market Size in the US

A dedicated section of the report focuses on the expected market size of AVASTIN for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders. 

What is AVASTIN Prescribed for?

Avastin is administered biweekly to patients with metastatic colorectal cancer (mCRC) who are initiating Avastin as part of their first- or second-line treatment. For those undergoing second-line treatment with Avastin after an initial treatment that included bevacizumab, the administration schedule shifts to every three weeks.

Why you should buy AVASTIN Market Report:

• The report provides future market assessments for AVASTIN for Glioblastoma Multiforme in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in Glioblastoma Multiforme.
• Leading AVASTIN for Glioblastoma Multiforme forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AVASTIN.
• Discover the competitive landscape of AVASTIN through 7MM
• Get a Thorough Analysis of the AVASTIN Development pipeline, Safety & Efficacy of the AVASTIN, and ROA
• Thorough AVASTIN market forecast will help understand how drug is competing with other emerging AVASTIN
• Get analysis of the AVASTIN clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Stay ahead in the competition by leveraging insights on the AVASTIN market Report: Download the AVASTIN Market Report

Related Reports

Glioblastoma Multiforme Market

DelveInsight’ s Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease.

Glioblastoma multiforme Pipeline Insight 2024

Glioblastoma Multiforme (GBM) Pipeline Insights, 2024 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Glioblastoma multiforme (GBM) market

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AVASTIN Market Size expected to increase many folds by 2032, reports DelveInsight

[Las Vegas, United States]  (29 January 2024) The Latest report, ZEJULA Market Size, Forecast, and Drug Insight 2032 is published by DelveInsight, a leader in healthcare research firm, providing insights into the ZEJULA market landscape and market forecast of ZEJULA up to 2032. This report is now available for review and analysis.

Are you interested in finding out the projected market size of ZEJULA in 2032? Click @ ZEJULA Market Size

The ZEJULA Market Report offers projected sales forecasts for ZEJULA for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and competitive landscape analysis of competitors and marketed products for Pancreatic Cancer. It also covers analyst views along with market drivers and barriers.

Do you know your drug’s competitive positioning against ZEJULA? Download Report: ZEJULA Market Outlook

ZEJULA is serving as a beacon of hope for patients suffering from Pancreatic Cancer.

ZEJULA is administered following a positive response (complete or partial) to platinum-based chemotherapy in the treatment of adults who have a specific inherited (germline) abnormal BRCA gene associated with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The report extensively covers the details and developments related to ZEJULA, capturing important highlights on the developmental pipeline, regulatory status and special designations of ZEJULA, route of administration, safety and efficacy details.

ZEJULA Market Assessment

This report provides a detailed market assessment of ZEJULA for Pancreatic Cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

ZEJULA Clinical Assessment

The report provides the clinical trials information of ZEJULA for Pancreatic Cancer covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.  

ZEJULA Competitive Landscape 

The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the ZEJULA.

ZEJULA Market Size in the US

A dedicated section of the report focuses on the expected market size of ZEJULA for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders. 

What is ZEJULA Prescribed for?

Zejula is approved for use as the sole treatment to maintain the health of adult patients with advanced high-grade ovarian, fallopian tube, or primary peritoneal cancer (FIGO Stages III and IV). This applies to individuals who have responded positively (either complete or partial response) after finishing their initial platinum-based chemotherapy.

Why you should buy ZEJULA Market Report:

• The report provides future market assessments for ZEJULA for Pancreatic Cancer in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in Pancreatic Cancer.
• Leading ZEJULA for Pancreatic Cancer forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZEJULA.
• Discover the competitive landscape of ZEJULA through 7MM
• Get a Thorough Analysis of the ZEJULA Development pipeline, Safety & Efficacy of the ZEJULA, and ROA
• Thorough ZEJULA market forecast will help understand how drug is competing with other emerging ZEJULA
• Get analysis of the ZEJULA clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Stay ahead in the competition by leveraging insights on the ZEJULA market Report: Download the ZEJULA Market Report

Pancreatic Cancer Market

DelveInsight’s Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Pancreatic Cancer Market.

Pancreatic Cancer Pipeline Insight 2024

Pancreatic Cancer Pipeline Insights, 2024 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects.

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ZEJULA Market Size expected to increase many folds by 2032, reports DelveInsight